Asia
HanchorBio Unit Files US IND Application for Trispecific Cancer Drug HCB303
FBD Biologics, a subsidiary of HanchorBio (TPE:7827), has submitted an investigational new drug application to the U.S. Food and Drug Administration for HCB303, a trispecific fusion protein biologic targeting solid tumors.The candidate has not yet entered human clinical trials or received commercial approval. Upon clearance, HanchorBio plans to advance it through Phase I to III evaluations.Global oncology therapeutics are estimated by IQVIA to be a $291 billion market expanding through 2030, HanchorBio said.
TPE:7827
